Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

855675P

Avanti

16:0 Lyso PC

Avanti Research - A Croda Brand

Sinonimo/i:

1-hexadecanoyl-sn-glycero-3-phosphocholine; PC(16:0/0:0)

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

25 MG
154,00 €
200 MG
194,00 €
500 MG
299,00 €
1 G
524,00 €

154,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
25 MG
154,00 €
200 MG
194,00 €
500 MG
299,00 €
1 G
524,00 €

About This Item

Formula empirica (notazione di Hill):
C24H50NO7P
Numero CAS:
Peso molecolare:
495.63
Numero MDL:
Codice UNSPSC:
51191904
NACRES:
NA.25

154,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Descrizione

1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine

Saggio

>99% (LPC; may contain up to 10% of the 2-LPC isomer, TLC)

Stato

powder

Confezionamento

pkg of 1 × 1 g (855675P-1g)
pkg of 1 × 200 mg (855675P-200mg)
pkg of 1 × 25 mg (855675P-25mg)
pkg of 1 × 500 mg (855675P-500mg)

Produttore/marchio commerciale

Avanti Research - A Croda Brand

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

Stringa SMILE

O[C@](COP([O-])(OCC[N+](C)(C)C)=O)([H])COC(CCCCCCCCCCCCCCC)=O

InChI

1S/C24H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24(27)30-21-23(26)22-32-33(28,29)31-20-19-25(2,3)4/h23,26H,5-22H2,1-4H3/t23-/m1/s1
ASWBNKHCZGQVJV-HSZRJFAPSA-N

Applicazioni


  • Microbubble-Mediated Drug Delivery: The role of 16:0 Lyso PC in the development of microbubble technologies for drug delivery systems emphasizes its potential in pharmaceutical formulations, enhancing the efficiency of targeted therapy applications, particularly in cancer treatment (Aron et al., 2019).

  • Photodynamic Therapy for Glioma: Research involving 16:0 Lyso PC in the context of biohybrid systems for light-activatable treatments showcases its application in medical therapies, particularly for treating challenging conditions like glioma through photodynamic therapy, underlining its potential in enhancing clinical outcomes (Inglut et al., 2019).

Confezionamento

20 mL Clear Glass Screw Cap Vial (855675P-1g)
20 mL Clear Glass Screw Cap Vial (855675P-500mg)
5 mL Amber Glass Screw Cap Vial (855675P-200mg)
5 mL Amber Glass Screw Cap Vial (855675P-25mg)

Note legali

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 10

1 of 10

2-16:0 Lyso PC Avanti Research™ - A Croda Brand

Avanti

855674P

2-16:0 Lyso PC

17:0 Lyso PC Avanti Research™ - A Croda Brand

Avanti

855676P

17:0 Lyso PC

18:1 Lyso PC 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine, chloroform

Avanti

845875C

18:1 Lyso PC

16:0 Lyso PG 1-palmitoyl-2-hydroxy-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt), powder

Avanti

858122P

16:0 Lyso PG

2-18:0 Lyso PC Avanti Research™ - A Croda Brand 855774P, powder

Avanti

855774P

2-18:0 Lyso PC

16:0 Lyso PI 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphoinositol (ammonium salt), powder

Avanti

850102P

16:0 Lyso PI

18:0 Lyso PE 1-Stearoyl-2-Hydroxy-sn-Glycero-3-Phosphoethanolamine, powder

Avanti

856715P

18:0 Lyso PE

18:1 Lyso PS Avanti Research™ - A Croda Brand

Avanti

858143P

18:1 Lyso PS

Egg Lyso PC Avanti Research™ - A Croda Brand

Avanti

830071P

Egg Lyso PC

16:0 lyso PC-d49 powder

Avanti

870308P

16:0 lyso PC-d49

Takafumi Enomoto et al.
Langmuir : the ACS journal of surfaces and colloids, 34(3), 750-755 (2017-10-06)
A major goal of synthetic biology is the development of rational methodologies to construct self-assembling non-natural membranes, which could enable the efficient fabrication of artificial cellular systems from purely synthetic components. However, spatiotemporal control of artificial membrane formation remains both
Xinyuan Li et al.
Redox biology, 28, 101373-101373 (2019-11-16)
It has been shown that anti-inflammatory cytokines interleukin-35 (IL-35) and IL-10 could inhibit acute endothelial cell (EC) activation, however, it remains unknown if and by what pathways IL-35 and IL-10 could block atherogenic lipid lysophosphatidylcholine (LPC)-induced sustained EC activation; and
Yoko Shima et al.
The Journal of biological chemistry, 295(20), 6983-6991 (2020-04-10)
Newly synthesized major histocompatibility complex (MHC) class I proteins are stabilized in the endoplasmic reticulum (ER) by binding 8-10-mer-long self-peptide antigens that are provided by transporter associated with antigen processing (TAP). These MHC class I:peptide complexes then exit the ER
Li V Yang et al.
Blood, 105(3), 1127-1134 (2004-09-24)
G2A is a G-protein-coupled receptor (GPCR) involved in immune regulation. Previous studies have shown that lysophosphatidylcholine (LPC), a bioactive lipid associated with atherosclerosis and autoimmunity, acts through G2A to induce diverse biologic effects. Production of LPC during cell apoptosis serves
Caius G Radu et al.
Proceedings of the National Academy of Sciences of the United States of America, 101(1), 245-250 (2003-12-19)
G2A is an immunoregulatory G protein-coupled receptor predominantly expressed in lymphocytes and macrophages. Ectopic overexpression studies have implicated G2A as a receptor for the bioactive lysophospholipid, lysophosphatidylcholine (LPC). However, the functional consequences of LPC-G2A interaction at physiological levels of receptor

Articoli

The critical micelle concentration (CMC) can be approximately defined as the lipid monomer concentration at which appreciable amounts (>5% of total) of micellar aggregates first begin to appear in the equilibrium: nM1<=>Mn

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.